Peptides for Anti-Ageing in Australia (Research)

The short answer

There is no peptide approved in Australia as an anti-ageing medicine. The compounds that appear in ageing and longevity discussions, such as MOTS-c, Epithalon and GHK-Cu, are research materials. Most of the evidence behind them comes from cell culture and animal studies, with only limited early work in humans. None of them are registered on the Australian Register of Therapeutic Goods as a treatment for ageing.

When these peptides are sold in Australia, they are supplied for laboratory and research use only, not for human use. That framing matters, because it reflects both their regulatory status and the genuine state of the science. This guide summarises what each compound is, the pathway researchers study it in, and how mature that research currently is.

What ageing research actually studies

In longevity science, researchers usually separate two ideas. Lifespan is how long an organism lives. Healthspan is how long it stays biologically functional. Most peptide work in this area targets specific cellular pathways thought to change with age, such as mitochondrial energy production, cellular senescence, telomere maintenance and the growth hormone axis.

It is worth being clear about what the research does not show. Pointing to a pathway that shifts with age is not the same as proving that adjusting it in a living human slows ageing or extends a healthy life. Much of the excitement around these compounds rests on early signals in simple models, and those signals frequently shrink or vanish when tested in people.

Pathways commonly examined

• Mitochondrial and metabolic signalling (for example MOTS-c)
• Telomere and telomerase biology (for example Epithalon)
• Collagen and skin matrix remodelling (for example GHK-Cu)
• Cellular energy cofactors such as NAD+
• The growth hormone and IGF-1 axis

MOTS-c, a mitochondrial-derived peptide

MOTS-c is a short peptide encoded within the mitochondrial 12S rRNA gene, first described in 2015. It belongs to a small family of mitochondrial-derived peptides. Researchers study it because it appears to act as a signalling molecule linking mitochondrial activity to broader metabolic control.

In published work, MOTS-c has been associated with the AMPK pathway, a central regulator of cellular energy balance. Studies report that MOTS-c can move to the cell nucleus under stress and influence genes involved in antioxidant and stress responses. Researchers have also noted that measured MOTS-c levels in blood and muscle tend to be lower in older subjects than in younger ones, which is why it is discussed in an ageing and metabolism context.

The evidence base is largely preclinical. Much of the most cited data comes from mouse and cell studies examining metabolism, insulin signalling and physical performance. This work is genuinely interesting at the mechanism level, but it is not the same as demonstrated anti-ageing benefit in humans.

Epithalon, a telomerase and pineal research peptide

Epithalon, also spelled Epitalon, is a synthetic four amino acid peptide with the sequence Ala-Glu-Asp-Gly. It was derived from Epithalamin, an extract of the pineal gland, and is studied as a short peptide that may influence telomerase, the enzyme that helps maintain telomeres at the ends of chromosomes.

The foundational work was published in the early 2000s by a Russian research group, which reported telomerase activity and telomere lengthening in human cells in culture. A later independent laboratory study also reported telomerase upregulation in certain normal cell types. Some animal studies have reported changes in median lifespan measures.

The limitations here are significant and should be stated plainly. The strongest telomere findings are from cell and animal work. There is no large, well controlled human trial showing that synthetic Epithalon lengthens human telomeres or slows human ageing, and a good deal of the human-relevant data traces back to a single research group and has not been broadly replicated. On current evidence, Epithalon is best understood as an early-stage research peptide.

GHK-Cu, the copper tripeptide

GHK-Cu is a copper-binding tripeptide made of glycine, histidine and lysine. It was first identified in human plasma in 1973 and is one of the most heavily studied peptides in skin science. Researchers examine its role in collagen and elastin signalling, tissue remodelling and the activity of a broad set of human genes.

GHK-Cu sits across two different contexts, which is a common point of confusion. As a topical cosmetic ingredient (often listed as copper tripeptide-1), it appears in serums and skincare sold in Australia and is studied for collagen and skin matrix effects. As a raw peptide intended for injection, it is a research material and is supplied for laboratory use only, not for human use. These are not the same thing and should not be treated as interchangeable.

On regulatory status, GHK-Cu is not registered on the ARTG as a therapeutic anti-ageing product, and the raw peptide is sold on a research-use-only basis. Its presence in cosmetic formulations is a separate category from injectable research material.

NAD+ and growth hormone axis peptides

Two further categories come up often in longevity discussions. The first is NAD+ and its precursors. NAD+ is a cofactor central to energy metabolism and cellular signalling, and cellular NAD+ tends to decline with age. Preclinical models suggest that restoring NAD+ can improve measures of healthspan, but human studies have generally shown much smaller effects than the animal work, and benefits for ageing in large human trials are not established.

The second is the growth hormone and IGF-1 axis, which various peptides are studied to influence. The relationship between this axis and longevity is complex and, in some model organisms, reduced growth hormone and IGF-1 signalling is associated with longer life rather than shorter. This is an active and unsettled research area, not a settled anti-ageing strategy.

Both categories are mentioned here for completeness. Neither represents an approved anti-ageing treatment in Australia, and both are discussed in a research context only.

Regulatory status in Australia

No peptide is approved by the TGA as an anti-ageing medicine. None of the compounds in this guide are registered on the Australian Register of Therapeutic Goods for that purpose. When supplied in Australia, they are provided for laboratory and research use only, not for human consumption or administration.

We do not list specific poisons schedule numbers here, because scheduling can vary by compound, form and intended use, and getting that wrong would be misleading. The accurate and conservative summary is that these are research materials, not approved anti-ageing medicines. The cosmetic use of a topical copper peptide is a separate matter from the research status of the injectable raw peptide.

The key points to remember

• None are TGA-approved anti-ageing medicines
• None are ARTG-registered for ageing or longevity
• Raw peptides are supplied for research use only
• Topical cosmetic copper peptides are a separate category
• Regulatory status is not the same as proven benefit

How to read the evidence critically

When assessing any longevity peptide, it helps to ask where the data comes from. Cell culture and animal results are the starting point of research, not the finish line. A compound that performs well in a dish or in mice can still fail to show meaningful effects in humans, and many do.

It is also worth noticing who conducted the research and whether it has been replicated independently. Findings confined to a single group, or to older studies that have not been reproduced, carry less weight than results confirmed across multiple laboratories. Marketing language that promises to reverse ageing or make you younger goes well beyond what the published science supports for any of these compounds.

A pathway that changes with age is a research lead, not a proven way to slow ageing in people.

Frequently asked questions